Z. Guo

发表

Modulation of p 53 , ErbB 1 , ErbB 2 , and Raf-1 Expression in Lung Cancer Cells by Depsipeptide FR 901228

L. Neckers, D. Schrump, D. Nguyen, 2002 .

Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228.

L. Neckers, D. Schrump, D. Nguyen, 2002, Journal of the National Cancer Institute.

Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses.

Z. Guo, D. Bartlett, S. Thorne, 2008, Biochimica et biophysica acta.

T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.

Z. Guo, D. Bartlett, Feng Yu, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Oncolytic Viruses as Platform for Multimodal Cancer Therapeutics: A Promising Land

Z. Guo, D. Bartlett, David L. Bartlett, 2014, Cancer Gene Therapy.

Specific transcription factors stimulate simian virus 40 and polyomavirus origins of DNA replication

M. DePamphilis, Z. Guo, Zong-Sheng Guo, 1992, Molecular and cellular biology.

A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus

H. Zeh, Z. Guo, D. Bartlett, 2007, Gene Therapy.

The Combination of Immunosuppression and Carrier Cells Significantly Enhances the Efficacy of Oncolytic Poxvirus in the Pre-Immunized Host

Z. Guo, D. Bartlett, M. Sathaiah, 2010, Gene Therapy.

CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy

Z. Guo, D. Bartlett, Zuqiang Liu, 2015, Oncoimmunology.

Oncolytic Poxvirus Armed with Fas Ligand Leads to Induction of Cellular Fas Receptor and Selective Viral Replication in FasR Negative Cancer

Z. Guo, D. Bartlett, M. Sathaiah, 2011, Cancer Gene Therapy.

The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2.

B. Moss, M. Lotze, A. Naik, 2005, Cancer research.

Antisense to SV40 early gene region induces growth arrest and apoptosis in T-antigen-positive human pleural mesothelioma cells.

D. Schrump, D. Nguyen, G. Chen, 1999, Cancer research.

Life after death: targeting high mobility group box 1 in emergent cancer therapies.

M. Lotze, D. Tang, Z. Guo, 2013, American journal of cancer research.

De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.

K. Irvine, Julie A Hong, D. Schrump, 2006, Cancer research.

Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy

Z. Guo, D. Bartlett, Zuqiang Liu, 2017, Nature Communications.

Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer.

Z. Guo, D. Bartlett, S. Thorne, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation

Z. Guo, D. Bartlett, Zuqiang Liu, 2021, Theranostics.

Redirecting adaptive immunity against foreign antigens to tumors for cancer therapy

S. Swisher, Wei Guo, B. Fang, 2007, Cancer biology & therapy.

Epitope‐optimized alpha‐fetoprotein genetic vaccines prevent carcinogen‐induced murine autochthonous hepatocellular carcinoma

D. Munn, L. Butterfield, Z. Guo, 2014, Hepatology.

JNK-deficiency enhanced oncolytic vaccinia virus replication and blocked activation of double-stranded RNA-dependent protein kinase

S. Swisher, W. Hofstetter, B. Fang, 2008, Cancer Gene Therapy.

Lentivector Prime and Vaccinia Virus Vector Boost Generate High-Quality CD8 Memory T Cells and Prevent Autochthonous Mouse Melanoma

Z. Guo, D. Bartlett, Yukai He, 2011, The Journal of Immunology.

Sequential 5-Aza-2′-deoxycytidine-Depsipeptide FR901228 Treatment Induces Apoptosis Preferentially in Cancer Cells and Facilitates Their Recognition by Cytolytic T Lymphocytes Specific for NY-ESO-1

F. Marincola, S. Rosenberg, Julie A Hong, 2001, Journal of immunotherapy.

Simian virus 40 origin auxiliary sequences weakly facilitate T-antigen binding but strongly facilitate DNA unwinding

M. DePamphilis, C. Gutiérrez, Z. Guo, 1990, Molecular and cellular biology.

5-AZA-2′-Deoxycytidine in Cancer Immunotherapy: A Mouse to Man Story

D. Schrump, Z. Guo, N. Restifo, 2007 .

Induction of MAGE-3 expression in lung and esophageal cancer cells.

Julie A Hong, D. Schrump, D. Nguyen, 2001, The Annals of thoracic surgery.

An optimal therapeutic expression level is crucial for suicide gene therapy for hepatic metastatic cancer in mice

K. Shirouzu, Z. Guo, K. Kosai, 2003, Hepatology.

Evaluation of promoter strength for hepatic gene expression in vivo following adenovirus-mediated gene transfer.

L. Wang, Z. Guo, S. Woo, 1996, Gene therapy.

Intravenous and isolated limb perfusion delivery of wild type and a tumor-selective replicating mutant vaccinia virus in nonhuman primates.

B. Moss, S. Chalikonda, S. Mocellin, 2005, Human gene therapy.

Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo.

R. Blasberg, D. Ballon, J. Koutcher, 1999, Cancer research.

Origin auxiliary sequences can facilitate initiation of simian virus 40 DNA replication in vitro as they do in vivo

M. DePamphilis, C. Gutiérrez, Z. Guo, 1989, Molecular and cellular biology.

Epigenetic drugs for cancer treatment and prevention: mechanisms of action

Z. Guo, Xiao-dan Yu, 2010, Biomolecular concepts.

The impact of hypoxia on oncolytic virotherapy

Z. Guo, 2011 .

Virus Adaptation and Treatment The impact of hypoxia on oncolytic virotherapy

Z. Guo, 2011 .

Local Administration of TLR Ligands Rescues the Function of Tumor-Infiltrating CD8 T Cells and Enhances the Antitumor Effect of Lentivector Immunization

D. Munn, Z. Guo, D. Bartlett, 2013, The Journal of Immunology.

Gene transfer: the challenge of regulated gene expression.

B. Fang, Z. Guo, D. Bartlett, 2008, Trends in molecular medicine.

Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene

S. Chalikonda, Xiao‐Yu Yin, H. Zeh, 2008, Cancer Gene Therapy.

Homeobox gene Rhox5 is regulated by epigenetic mechanisms in cancer and stem cells and promotes cancer growth

Z. Guo, D. Bartlett, Qiang Li, 2011, Molecular Cancer.

Three Epigenetic Drugs Up-Regulate Homeobox Gene Rhox5 in Cancer Cells through Overlapping and Distinct Molecular Mechanisms

M. Gorry, Z. Guo, D. Bartlett, 2009, Molecular Pharmacology.

TRAIL Gene-Armed Oncolytic Poxvirus and Oxaliplatin Can Work Synergistically against Colorectal Cancer

Yong J. Lee, B. Fang, Z. Guo, 2010, Gene Therapy.

Vaccinia Viral Vectors for Vaccines and Oncolytic Virotherapy

Z. Guo, D. Bartlett, J. McCart, 2015 .

Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2

Z. Guo, D. Bartlett, Zuqiang Liu, 2018, Nature Communications.

Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer.

J. Flynn, M. Smyth, P. Darcy, 2012, Cancer research.

Vaccinia as a vector for gene delivery

Z. Guo, D. Bartlett, 2004, Expert opinion on biological therapy.

Is c-myc protein directly involved in DNA replication?

M. DePamphilis, C. Gutiérrez, W. Burhans, 1988, Science.

c-myc protein and DNA replication: separation of c-myc antibodies from an inhibitor of DNA synthesis

M. DePamphilis, C. Gutiérrez, Z. Guo, 1987, Molecular and cellular biology.

T-antigen binding to site I facilitates initiation of SV40 DNA replication but does not affect bidirectionality.

M. DePamphilis, Z. Guo, U. Heine, 1991, Nucleic acids research.

The efficacy of adenovirus-mediated gene therapy of ovarian cancer is enhanced by using the cytomegalovirus promoter.

C. Contant, Z. Guo, A. Hasenburg, 1998, Anticancer research.

Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system.

J. Gu, J. Roth, P. Koch, 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

High Mobility Group B1 Protein Suppresses the Human Plasmacytoid Dendritic Cell Response to TLR9 Agonists1

K. Tracey, M. Lotze, H. Zeh, 2006, The Journal of Immunology.

Gene transfer: the challenge of regulated gene expression

B. Fang, Z. Guo, D. Bartlett, 2008 .

Inhibitors of C5 complement enhance vaccinia virus oncolysis

Z. Guo, D. Bartlett, R. Ravindranathan, 2013, Cancer Gene Therapy.

T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.

Z. Guo, D. Bartlett, Feng Yu, 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

Epitope‐optimized alpha‐fetoprotein genetic vaccines prevent carcinogen‐induced murine autochthonous hepatocellular carcinoma

D. Munn, L. Butterfield, Z. Guo, 2014, Hepatology.

This information is current as Response to TLR 9 Agonists the Human Plasmacytoid Dendritic Cell High Mobility Group B 1 Protein Suppresses

K. Tracey, M. Lotze, Z. Guo, 2006 .